Compare CXT & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXT | BCRX |
|---|---|---|
| Founded | 1855 | 1986 |
| Country | United States | United States |
| Employees | N/A | 435 |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.5B |
| IPO Year | 1994 | 1995 |
| Metric | CXT | BCRX |
|---|---|---|
| Price | $50.13 | $9.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $73.00 | $20.82 |
| AVG Volume (30 Days) | 503.0K | ★ 3.2M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | N/A | ★ 381.40 |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $3,374,900,000.00 | $25,186,000.00 |
| Revenue This Year | $5.75 | N/A |
| Revenue Next Year | $4.22 | $12.55 |
| P/E Ratio | $69.04 | ★ N/A |
| Revenue Growth | ★ 6.13 | N/A |
| 52 Week Low | $35.71 | $6.00 |
| 52 Week High | $69.00 | $11.22 |
| Indicator | CXT | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.00 | 51.75 |
| Support Level | $47.01 | $8.79 |
| Resistance Level | $53.40 | $10.01 |
| Average True Range (ATR) | 1.55 | 0.42 |
| MACD | -0.25 | 0.00 |
| Stochastic Oscillator | 35.58 | 27.54 |
Crane NXT Co is a industrial technology company that provides proprietary and trusted technology solutions to secure, detect, and authenticate what matters to its customers. It is a pioneer in proprietary micro-optics technology for securing physical products, and its sophisticated electronic equipment and associated software leverages proprietary core capabilities with detection and sensing technologies. The company operates in two segments which are Crane Payment Innovations (CPI) and Security and Authentication Technologies.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.